- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01631630
Role of Proinflammatory Signaling in Alcohol Craving
Background:
- Drinking too much alcohol can injure cells in the body. Inflammation is the body s reaction to injured cells. Studies show that inflammation can cause cravings for alcohol. Researchers want to see if pioglitazone, a drug that decreases inflammation, can reduce alcohol craving. If so, it might help develop new ways to help alcoholics with craving.
Objectives:
- To see if pioglitazone can reduce alcohol craving.
Eligibility:
- Adults between 21 and 65 years of age who are alcoholic and have been drinking within the past month.
Design:
- Participants will be screened with a physical exam and medical history. Blood samples will also be collected.
- All participants will have inpatient treatment at the National Institutes of Health Clinical Center for the 5 weeks of the study. They will have standard treatment for alcoholism during their inpatient stay.
- Half of the people in this study will have pioglitazone. The other half will have a placebo.
- Participants will have different studies during their stay. These studies will include the following:
- Personalized audio recordings of stressful, alcohol-related, and neutral events to monitor mood
- Imaging studies to test alcohol cravings
- Questionnaires about mood and alcohol cravings
- Lumbar puncture to collect spinal fluid
- Inflammation test to see if the study drug can block alcohol cravings
- After the end of the 5-week study, all participants will be offered follow-up outpatient care through the Clinical Center, or referral to outside treatment.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Objective: The objective of the present study is to evaluate the role of proinflammatory signaling in alcohol craving. The peroxisome proliferator-activated receptor y (PPARy) agonist pioglitazone, which modulates glial activity, will be used as an experimental treatment. Guided imagery auditory scripts will be used as an established set of stimuli to induce craving. Low dose lipopolysaccharide (LPS) administration which activates proinflammatory signaling will be used as a novel challenge, and evaluated for its ability to provoke alcohol craving. If LPS in fact induces alcohol craving, the present design will allow evaluation of whether pioglitazone can inhibit this response.
Study population: Up to 60 subjects will be recruited for a target accrual of 50 completers. Subjects will be aged 21-65 years, with alcohol dependence as their primary complaint, and without other serious medical or psychiatric conditions. They will be admitted to the NIAAA research inpatient unit at the NIH Clinical Research Center (CRC) through one of the screening protocols (05-AA-0121 Assessment and Treatment of People with Alcohol Drinking Problems ) or 14-AA-0181 "Unit and Clinic Evaluations, Screening, Assessment, and Management") which provides basic assessments and standard withdrawal treatment if needed.
Design: Following inclusion, subjects will undergo interviews for construction of guided imagery scripts, and these scripts will subsequently be used as stress-, alcohol- or neutral condition associated stimuli. Subjects will be randomized to pioglitazone (n=25; final dose: 45mg/daily) or identically looking placebo (n=25). Following at least two weeks of treatment, subjects will undergo three sessions of guided imagery, on separate days and in a counter-balanced order, exposing them to the personalized stress-, alcohol- or neutral condition associated auditory scripts, respectively. During the final week, subjects will undergo two challenge sessions, a minimum of five days apart, with lipopolysaccharide (LPS) or placebo, in counterbalanced order.
Outcome measures: Subjective ratings of mood, anxiety and craving will be obtained twice weekly throughout the study. During the challenge sessions that utilize psychological stimuli or LPS, subjective ratings of craving for alcohol, as well as ratings of negative emotions will be obtained. Lumbar puncture will be performed and cerebrospinal fluid (CSF) obtained to determine the effect of pioglitazone on levels of proinflammatory cytokines. Neuroendocrine, psychological and physiological measures will be collected for exploratory purposes. An fMRI scan will be obtained to evaluate the effect of pioglitazone on BOLD signal in response to emotionally salient visual cues.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
INCLUSION CRITERIA:
- Diagnostic and Statistical Manual (DSM)-IV diagnosis of alcohol dependence on Structured Clinical Interview for DSM Diagnosis (SCID) alcohol problems as primary complaint among substance use disorders, and alcohol use within the last month.
- Age 21 65
- Right handed
For women:
- post-menopausal or surgically sterile (tubal ligation or hysterectomy); or
- if sexually active with a male partner and able to get pregnant, documented agreement to use an effective form of birth control. Acceptable forms of contraception for this study include: hormonal contraceptives (birth-control pills, injectable hormones, vaginal-ring hormones); intrauterine device (IUD); diaphragm with spermicide; condom with spermicide.
EXCLUSION CRITERIA:
Any medical illness that in the view of the investigators would compromise participation in research, as determined by medical history, physical examination, laboratory tests (see details under Screening measures below), including, but not limited to:
- Diabetes mellitus Type I or Type II
- Past or current diagnosis of congestive heart failure
- Signs and symptoms suggestive of congestive heart failure
- Cardiovascular disease (e.g., history of congenital heart defect, heart disease, symptomatic coronary-artery disease, heart attack, clinically significant arrhythmia, etc.)
- Cerebrovascular disease
- Infection, autoimmune disease, or fever of unknown origin
- Unexplained history of syncope
- History of seizures, except for febrile seizures during childhood
- History of head injury with loss of consciousness of more than 30 minutes or with postconcussive sequelae lasting more than two days, regardless of loss of consciousness
- Chronic renal failure as estimated by glomerular filtration rate (GFR) <60 milliliters per minute 1.73 per Square
- HIV infection
- Active bladder cancer, history of bladder cancer, or persistent hematuria
- Allergy, hypersensitivity, or intolerance to pioglitazone, other thiazolidinediones, or the metabolites of any of those drugs (determined by medical history)
- Pregnancy or breastfeeding (urine pregnancy test; self-report)
- Diabetes medications (e.g., sulfonylureas, metformin, insulin, etc.)
- Contraindicated or strongly interacting medications: Gemfibrozil (inhibitor of CYP2C8) and rifampin (inducer of CYP2C8), atorvastatin, ketoconazole, nifedipine
- Any ongoing, or regular use of central nervous system (CNS) active medications within the last week (fluoxetine: last 4 weeks), with the exception of withdrawal medication, obtained according to the NIAAA clinical guidelines if needed
- Use of docosahexaenoic acid (DHA) dietary supplements, or consumption of oily fish >3 times per week (because of effects of DHA on inflammatory parameters)
- History of Rhabdomyolysis
Psychiatric history:
- Cognitive impairment severe enough to preclude informed consent or valid responses on questionnaires, as established by clinical exam, in questionable cases aided by a Mini Mental State Examination (with a score of <21, indicating more than mild cognitive impairment, being exclusionary)
- Current diagnosis of schizophrenia or any other DSM-IV psychotic disorder, bipolar disorder, or major depressive disorder, in each case as established by clinical evaluation and SCID.
Substance use disorders:
- Current alcohol intoxication on breathalyzer test or positive urine drug screen on enrollment
- Current dependence on drugs other than alcohol or nicotine, as established by SCID interview
Inability or unwillingness to participate in an fMRI scan, including
- Presence of ferromagnetic objects in the body that are contraindicated for MRI of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments) or fear of enclosed spaces. Eligibility will be determined by a MRI Safety Screening Questionnaire and verified, if necessary, by a physician.
- Subjects that cannot lie comfortably flat on their back for up to 2 hours in the MRI scanner.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Pioglitazone
Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
|
Pioglitazone is a thiazolidinedione antidiabetic.
It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
Altri nomi:
|
Comparatore placebo: Placebo
Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
|
Placebo is an inactive tablet design to look exactly like pioglitazone
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Alcohol Cue Script
Lasso di tempo: 90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Lasso di tempo: 15 minutes prior to the subject receiving an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
15 minutes prior to the subject receiving an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Lasso di tempo: 1 hour after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
1 hour after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Lasso di tempo: 2 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
2 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Lasso di tempo: 3 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
3 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Lasso di tempo: 4 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
4 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Lasso di tempo: 5 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
5 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol Craving in Response to the Lipopolysaccharide Challenge
Lasso di tempo: 6 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
6 hours after the subject received an intravenous bolus of lipopolysaccharide, which occurred on Day 25 or Day 32 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
15 minutes prior to the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
15 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
5 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
30 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
45 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
60 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
75 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol Craving in Response to the Stress Script
Lasso di tempo: 90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Alcohol craving was measured using the Alcohol Urges Questionnaire (AUQ).
The AUQ is an 8-item self-administered instrument that assesses craving for alcohol among alcohol users in the current context (i.e., right now).
The score ranges from 8 (lowest craving value) to 56 (highest craving value).
|
90 minutes after the beginning of script presentation, which occurred on Day 21, 22, or 23 of the treatment period
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Valutazioni dei sintomi di ansia misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 1 del periodo di trattamento
|
I sintomi di ansia sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 1 del periodo di trattamento
|
Valutazioni dei sintomi di ansia misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 14 del periodo di trattamento
|
I sintomi di ansia sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 14 del periodo di trattamento
|
Valutazioni dei sintomi di ansia misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 21 del periodo di trattamento
|
I sintomi di ansia sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 21 del periodo di trattamento
|
Valutazioni dei sintomi di ansia misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 28 del periodo di trattamento
|
I sintomi di ansia sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 28 del periodo di trattamento
|
Valutazioni dei sintomi di ansia misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 7 del periodo di trattamento
|
I sintomi di ansia sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 7 del periodo di trattamento
|
Valutazioni dei sintomi della depressione misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 1 del periodo di trattamento
|
I sintomi della depressione sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 1 del periodo di trattamento
|
Valutazioni dei sintomi della depressione misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 14 del periodo di trattamento
|
I sintomi della depressione sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 14 del periodo di trattamento
|
Valutazioni dei sintomi della depressione misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 21 del periodo di trattamento
|
I sintomi della depressione sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 21 del periodo di trattamento
|
Valutazioni dei sintomi della depressione misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 28 del periodo di trattamento
|
I sintomi della depressione sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 28 del periodo di trattamento
|
Valutazioni dei sintomi della depressione misurate bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 7 del periodo di trattamento
|
I sintomi della depressione sono stati misurati utilizzando la scala di valutazione psicopatologica completa (CPRS).
Il CPRS è uno strumento basato su interviste di 18 item per valutare la depressione e l'ansia.
Ci sono due sottoscale di 10 item, la Montgomery-Asberg Depression Rating Scale (MADRS) e la Brief Scale for Anxiety (BSA).
Ogni sottoscala varia da 0 (gravità dei sintomi più bassa) a 60 (gravità dei sintomi più alta).
|
Giorno 7 del periodo di trattamento
|
Desiderio spontaneo di alcol misurato bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 1 del periodo di trattamento
|
Il desiderio di alcol è stato misurato utilizzando la Penn Alcohol Craving Scale (PACS).
Il PACS è uno strumento autosomministrato a cinque voci per valutare il desiderio di alcol nel corso dell'ultima settimana.
Il punteggio va da 0 (valore craving più basso) a 30 (valore craving più alto).
|
Giorno 1 del periodo di trattamento
|
Desiderio spontaneo di alcol misurato bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 14 del periodo di trattamento
|
Il desiderio di alcol è stato misurato utilizzando la Penn Alcohol Craving Scale (PACS).
Il PACS è uno strumento autosomministrato a cinque voci per valutare il desiderio di alcol nel corso dell'ultima settimana.
Il punteggio va da 0 (valore craving più basso) a 30 (valore craving più alto).
|
Giorno 14 del periodo di trattamento
|
Desiderio spontaneo di alcol misurato bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 21 del periodo di trattamento
|
Il desiderio di alcol è stato misurato utilizzando la Penn Alcohol Craving Scale (PACS).
Il PACS è uno strumento autosomministrato a cinque voci per valutare il desiderio di alcol nel corso dell'ultima settimana.
Il punteggio va da 0 (valore craving più basso) a 30 (valore craving più alto).
|
Giorno 21 del periodo di trattamento
|
Desiderio spontaneo di alcol misurato bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 28 del periodo di trattamento
|
Il desiderio di alcol è stato misurato utilizzando la Penn Alcohol Craving Scale (PACS).
Il PACS è uno strumento autosomministrato a cinque voci per valutare il desiderio di alcol nel corso dell'ultima settimana.
Il punteggio va da 0 (valore craving più basso) a 30 (valore craving più alto).
|
Giorno 28 del periodo di trattamento
|
Desiderio spontaneo di alcol misurato bisettimanalmente durante il periodo di trattamento
Lasso di tempo: Giorno 7 del periodo di trattamento
|
Il desiderio di alcol è stato misurato utilizzando la Penn Alcohol Craving Scale (PACS).
Il PACS è uno strumento autosomministrato a cinque voci per valutare il desiderio di alcol nel corso dell'ultima settimana.
Il punteggio va da 0 (valore craving più basso) a 30 (valore craving più alto).
|
Giorno 7 del periodo di trattamento
|
Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 3 of the treatment period
|
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 3 of the treatment period
|
Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 10 of the treatment period
|
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 10 of the treatment period
|
Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 17 of the treatment period
|
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 17 of the treatment period
|
Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 24 of the treatment period
|
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 24 of the treatment period
|
Anxiety Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 31 of the treatment period
|
Anxiety symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 31 of the treatment period
|
Depression Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 3 of the treatment period
|
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 3 of the treatment period
|
Depression Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 10 of the treatment period
|
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 10 of the treatment period
|
Depression Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 17 of the treatment period
|
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 17 of the treatment period
|
Depression Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 24 of the treatment period
|
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 24 of the treatment period
|
Depression Symptom Ratings Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 31 of the treatment period
|
Depression symptoms were measured using the Comprehensive Psychopathological Rating Scale (CPRS).
The CPRS is an 18-item interview-based instrument for assessing depression and anxiety.
There are two 10-item subscales, the Montgomery-Asberg Depression Rating Scale (MADRS) and the Brief Scale for Anxiety (BSA).
Each subscale ranges from 0 (lowest symptom severity) to 60 (highest symptom severity).
|
Day 31 of the treatment period
|
Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 3 of the treatment period
|
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS).
The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week.
The score ranges from 0 (lowest craving value) to 30 (highest craving value).
|
Day 3 of the treatment period
|
Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 10 of the treatment period
|
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS).
The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week.
The score ranges from 0 (lowest craving value) to 30 (highest craving value).
|
Day 10 of the treatment period
|
Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 17 of the treatment period
|
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS).
The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week.
The score ranges from 0 (lowest craving value) to 30 (highest craving value).
|
Day 17 of the treatment period
|
Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 24 of the treatment period
|
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS).
The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week.
The score ranges from 0 (lowest craving value) to 30 (highest craving value).
|
Day 24 of the treatment period
|
Spontaneous Alcohol Craving Measured Bi-weekly During the Treatment Period
Lasso di tempo: Day 31 of the treatment period
|
Alcohol craving was measured using the Penn Alcohol Craving Scale (PACS).
The PACS is a five-item self-administered instrument for assessing alcohol craving over the course of the past week.
The score ranges from 0 (lowest craving value) to 30 (highest craving value).
|
Day 31 of the treatment period
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007 Feb;21(2):153-60. doi: 10.1016/j.bbi.2006.09.006. Epub 2006 Nov 7.
- Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011 May;130(2):226-38. doi: 10.1016/j.pharmthera.2011.01.014. Epub 2011 Feb 17.
- Crews FT, Zou J, Qin L. Induction of innate immune genes in brain create the neurobiology of addiction. Brain Behav Immun. 2011 Jun;25 Suppl 1(Suppl 1):S4-S12. doi: 10.1016/j.bbi.2011.03.003. Epub 2011 Mar 21.
- Schwandt ML, Diazgranados N, Umhau JC, Kwako LE, George DT, Heilig M. PPARgamma activation by pioglitazone does not suppress cravings for alcohol, and is associated with a risk of myopathy in treatment seeking alcohol dependent patients: a randomized controlled proof of principle study. Psychopharmacology (Berl). 2020 Aug;237(8):2367-2380. doi: 10.1007/s00213-020-05540-w. Epub 2020 May 22.
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 120143
- 12-AA-0143 (Altro identificatore: NIH)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Bere alcolici
-
Mayo ClinicJames and Esther King Biomedical Research ProgramCompletatoIntervento comportamentale integrato per il fumo di sigaretta e il binge drinking nei giovani adultiper la cessazione del fumo di sigaretta e del binge drinkingStati Uniti
-
HBSAReclutamentoBinge drinking, consumo di alcol da parte di minorenni, guida in stato di ebbrezza, danni correlati all'alcolStati Uniti